FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229367629> ?p ?o ?g. }

• W4229367629 endingPage "1202" @default.
• W4229367629 startingPage "1187" @default.
• W4229367629 abstract "The clinical benefits of insulin glargine 300 U/mL (Gla-300) have been confirmed in randomised clinical trials (EDITION programme and BRIGHT) and real-world studies in the USA and Western Europe. ATOS evaluated the real-world effectiveness and safety of Gla-300 in wider geographic regions (Asia, the Middle East, North Africa, Latin America and Eastern Europe). This prospective observational, international study enrolled adults (≥ 18 years) with type 2 diabetes mellitus (T2DM) uncontrolled [haemoglobin A1c (HbA1c) > 7% to ≤ 11%] on one or more oral anti-hyperglycaemic drugs (OADs) who had been advised by their treating physician to add Gla-300 to their existing treatment. The primary endpoint was achievement of a pre-defined individualised HbA1c target at month 6. Of the 4550 participants included, 4422 (51.8% female) were eligible for assessment. The mean ± standard deviation (SD) age was 57.2 ± 10.8 years, duration of diabetes was 10.2 ± 6.2 years and baseline HbA1c was 9.28 ± 1.0%. The proportion of participants reaching their individualised glycaemic target was 25.2% [95% confidence interval (CI) 23.8–26.6%] at month 6 and 44.5% (95% CI 42.9–46.1%) at month 12. At months 6 and 12, reductions were observed in HbA1c (−1.50% and −1.87%) and fasting plasma glucose (−3.42 and −3.94 mmol/L). Hypoglycaemia incidence was low, and body weight change was minimal. Adverse events were reported in 283 (6.4%) participants, with 57 (1.3%) experiencing serious adverse events. In a real-world setting, initiation of Gla-300 in people with T2DM uncontrolled on OADs resulted in improved glycaemic control and low rates of hypoglycaemia with minimal weight change. Clinicaltrials.gov number NCT03703869." @default.
• W4229367629 created "2022-05-10" @default.
• W4229367629 creator A5018431097 @default.
• W4229367629 creator A5038075336 @default.
• W4229367629 creator A5041274229 @default.
• W4229367629 creator A5052718594 @default.
• W4229367629 creator A5052999942 @default.
• W4229367629 creator A5085250646 @default.
• W4229367629 creator A5090518763 @default.
• W4229367629 creator A5091150762 @default.
• W4229367629 date "2022-05-09" @default.
• W4229367629 modified "2023-10-10" @default.
• W4229367629 title "Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study" @default.
• W4229367629 cites W1485225507 @default.
• W4229367629 cites W1513833217 @default.
• W4229367629 cites W1545770620 @default.
• W4229367629 cites W1726580060 @default.
• W4229367629 cites W1744831875 @default.
• W4229367629 cites W2014937695 @default.
• W4229367629 cites W2021922953 @default.
• W4229367629 cites W2038913714 @default.
• W4229367629 cites W2053071191 @default.
• W4229367629 cites W2100633491 @default.
• W4229367629 cites W2105153491 @default.
• W4229367629 cites W2116839562 @default.
• W4229367629 cites W2139040359 @default.
• W4229367629 cites W2145290170 @default.
• W4229367629 cites W2156355127 @default.
• W4229367629 cites W2338167986 @default.
• W4229367629 cites W2531918455 @default.
• W4229367629 cites W2555972020 @default.
• W4229367629 cites W2620406790 @default.
• W4229367629 cites W2765159569 @default.
• W4229367629 cites W2777315381 @default.
• W4229367629 cites W2801104021 @default.
• W4229367629 cites W2887818979 @default.
• W4229367629 cites W2914739803 @default.
• W4229367629 cites W2922359495 @default.
• W4229367629 cites W2947726625 @default.
• W4229367629 cites W2991803878 @default.
• W4229367629 cites W2996274251 @default.
• W4229367629 cites W2998597229 @default.
• W4229367629 cites W3003977931 @default.
• W4229367629 cites W3005497627 @default.
• W4229367629 cites W4230570152 @default.
• W4229367629 doi "https://doi.org/10.1007/s13300-022-01266-4" @default.
• W4229367629 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35532858" @default.
• W4229367629 hasPublicationYear "2022" @default.
• W4229367629 type Work @default.
• W4229367629 citedByCount "5" @default.
• W4229367629 countsByYear W42293676292022 @default.
• W4229367629 crossrefType "journal-article" @default.
• W4229367629 hasAuthorship W4229367629A5018431097 @default.
• W4229367629 hasAuthorship W4229367629A5038075336 @default.
• W4229367629 hasAuthorship W4229367629A5041274229 @default.
• W4229367629 hasAuthorship W4229367629A5052718594 @default.
• W4229367629 hasAuthorship W4229367629A5052999942 @default.
• W4229367629 hasAuthorship W4229367629A5085250646 @default.
• W4229367629 hasAuthorship W4229367629A5090518763 @default.
• W4229367629 hasAuthorship W4229367629A5091150762 @default.
• W4229367629 hasBestOaLocation W42293676291 @default.
• W4229367629 hasConcept C120665830 @default.
• W4229367629 hasConcept C121332964 @default.
• W4229367629 hasConcept C126322002 @default.
• W4229367629 hasConcept C134018914 @default.
• W4229367629 hasConcept C187212893 @default.
• W4229367629 hasConcept C197934379 @default.
• W4229367629 hasConcept C203092338 @default.
• W4229367629 hasConcept C23131810 @default.
• W4229367629 hasConcept C2777180221 @default.
• W4229367629 hasConcept C2779306644 @default.
• W4229367629 hasConcept C2779920387 @default.
• W4229367629 hasConcept C2910068830 @default.
• W4229367629 hasConcept C44249647 @default.
• W4229367629 hasConcept C535046627 @default.
• W4229367629 hasConcept C555293320 @default.
• W4229367629 hasConcept C61511704 @default.
• W4229367629 hasConcept C71924100 @default.
• W4229367629 hasConceptScore W4229367629C120665830 @default.
• W4229367629 hasConceptScore W4229367629C121332964 @default.
• W4229367629 hasConceptScore W4229367629C126322002 @default.
• W4229367629 hasConceptScore W4229367629C134018914 @default.
• W4229367629 hasConceptScore W4229367629C187212893 @default.
• W4229367629 hasConceptScore W4229367629C197934379 @default.
• W4229367629 hasConceptScore W4229367629C203092338 @default.
• W4229367629 hasConceptScore W4229367629C23131810 @default.
• W4229367629 hasConceptScore W4229367629C2777180221 @default.
• W4229367629 hasConceptScore W4229367629C2779306644 @default.
• W4229367629 hasConceptScore W4229367629C2779920387 @default.
• W4229367629 hasConceptScore W4229367629C2910068830 @default.
• W4229367629 hasConceptScore W4229367629C44249647 @default.
• W4229367629 hasConceptScore W4229367629C535046627 @default.
• W4229367629 hasConceptScore W4229367629C555293320 @default.
• W4229367629 hasConceptScore W4229367629C61511704 @default.
• W4229367629 hasConceptScore W4229367629C71924100 @default.
• W4229367629 hasFunder F4320307781 @default.
• W4229367629 hasIssue "6" @default.
• W4229367629 hasLocation W42293676291 @default.

• next